Company intelligence / Profile preview

arcoris bio AG

Ownership: Private
Development stage: Preclinical

Overview

arcoris bio AG develops innovative technologies to enable spatial multiomics, multiplexed imaging, and advanced biomolecule detection. Their proprietary MUSE nanotechnology platform supports applications such as RNA FISH, immunofluorescence, IHC, and flow cytometry. The company’s solutions are used by leading academic researchers to overcome technical barriers in molecular imaging.[1][2] There is no evidence they have clinical programs or results.

Modalities: RNA FISH (Fluorescence In Situ Hybridization)ImmunofluorescenceIHC (Immunohistochemistry)FACS (Fluorescence Activated Cell Sorting)
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on arcoris bio AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on arcoris bio AG.

Explore the full profile